Company: SUNE
Filing Date: 2025-04-07
Form Type: 424B5
Source: 0001213900-25-029179
Chunk: 19

Company: SUNation Energy, Inc.
Filing Date: 2025-04-07
Form: 424B5
Chunk 19
---
 date of such Fundamental Transaction,
which may materially adversely affect our financial condition and/or results of operations and may prevent or deter a third party from
acquiring us.

Our shares will be subject to potential delisting if we do not maintain the listing requirements of the Nasdaq Capital Market.

The shares of our common stock
are listed on the Nasdaq Capital Market, or Nasdaq. Nasdaq has rules for continued listing, including, without limitation, minimum market
capitalization and other requirements. Failure to maintain our listing, or de-listing from Nasdaq, would make it more difficult for shareholders
to dispose of our common stock and more difficult to obtain accurate price quotations on our common stock. This could have an adverse
effect on the price of our common stock. Our ability to issue additional securities for financing or other purposes, or otherwise to arrange
for any financing we may need in the future, may also be materially and adversely affected if our common stock is not traded on a national
securities exchange.

While we believe we are currently compliant with
all applicable Nasdaq listing rules, we have in the past been subject to certain non-compliance notices. If we were to receive a new non-compliance
notice, many companies would normally be afforded a 180-calendar day period (“Cure Period”) to demonstrate compliance with,
e.g., the Minimum Bid Price Requirement. However, pursuant to the previously disclosed Nasdaq hearing panel decision, dated July 18, 2024,
the Company was subject to a mandatory panel monitor (“Panel”) under Nasdaq’s listing Rule 5815(d)(4)(B) for a period
of one year. Accordingly, moving forward, if we were to be notified of a Nasdaq non-compliance issue, we expect that the Staff would notified
the Company that it will not be afforded a Cure Period. Instead, the Company would likely be offered an opportunity to appeal any deficiency
related to a delisting determination to Nasdaq by a date certain. To this end, and by way of example, as a result of the price reset features
contained in the common warrants being offering in this offering, we believe there is a substantial possibility that our price per share
may fall below the minimum Nasdaq listing price of $1.00 per share. Accordingly, we may be subject to a delisting in such circumstance,
and unless the Company were to timely request a hearing before a Hearings Panel, the Company’s securities would be subject to suspension/delisting.
We cannot give assurances that